Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells.

[1]  R. Fanin,et al.  Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B‐CLL) cells , 2005, Journal of cellular physiology.

[2]  Hyun B Choi,et al.  IL-8 enhancement of amyloid-beta (Aβ1-42)-induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia , 2005, Journal of Neuroimmunology.

[3]  J. Gribben,et al.  Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. , 2004, Blood.

[4]  Lisa L. Smith,et al.  A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. , 2004, Blood.

[5]  C. Patrono,et al.  Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. , 2004, Experimental hematology.

[6]  S. Pileri,et al.  Histopathology of B-cell chronic lymphocytic leukemia. , 2004, Hematology/oncology clinics of North America.

[7]  S. Grösch,et al.  Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. , 2004, Biochemical pharmacology.

[8]  I. Morita,et al.  Constitutive Expression and Involvement of Cyclooxygenase-2 in Human Megakaryocytopoiesis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[9]  H. McKnight,et al.  Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. , 2004, Leukemia research.

[10]  K. Subbaramaiah,et al.  Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. , 2003, Cancer cell.

[11]  J. Kolb,et al.  Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. , 2003, Current drug targets. Cardiovascular & haematological disorders.

[12]  G. Gasparini,et al.  Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? , 2003, The Lancet. Oncology.

[13]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Kruhøffer,et al.  The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. , 2003, Blood.

[15]  D. L. Wilson,et al.  IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells , 2003, Leukemia.

[16]  K. Subbaramaiah,et al.  Cyclooxygenase 2: a molecular target for cancer prevention and treatment. , 2003, Trends in pharmacological sciences.

[17]  C. Peschel,et al.  Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. , 2002, Blood.

[18]  G. Cohen,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia , 2002, Oncogene.

[19]  M. Angelopoulou,et al.  B‐chronic lymphocytic leukemia: practical aspects , 2002, Hematological oncology.

[20]  C. Patrono,et al.  Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Colomer,et al.  Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. , 2002, Blood.

[22]  D. Goldenberg,et al.  Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. , 2002, Cancer research.

[23]  Ash A. Alizadeh,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[24]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[25]  P. Secchiero,et al.  Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. , 2001, Blood.

[26]  M. Murakami,et al.  Coupling between Cyclooxygenase, Terminal Prostanoid Synthase, and Phospholipase A2 * , 2001, The Journal of Biological Chemistry.

[27]  G. FitzGerald,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[28]  H. Döhner,et al.  CDNA microarray gene expression analysis of B‐cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking , 2001, International journal of cancer.

[29]  J. Binet,et al.  When and how to treat chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[30]  S. Ōmura,et al.  Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. , 2000, Blood.

[31]  L. Marnett,et al.  Xenobiotic-metabolizing Cytochromes P450 Convert Prostaglandin Endoperoxide to Hydroxyheptadecatrienoic Acid and the Mutagen, Malondialdehyde* , 2000, The Journal of Biological Chemistry.

[32]  A. Hsu,et al.  The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2* , 2000, The Journal of Biological Chemistry.

[33]  A. Levine,et al.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. , 1998, Cancer research.

[34]  E. Montserrat,et al.  Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. , 1998, Blood.

[35]  Y. Takei,et al.  Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. , 1998, The American journal of physiology.

[36]  D. Scollard,et al.  Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. , 1998, Journal of the National Cancer Institute.

[37]  N. Yoshimi,et al.  Apoptosis Induced by NS‐398, a Selective Cyclooxygenase‐2 Inhibitor, in Human Colorectal Cancer Cell Lines , 1997, Japanese journal of cancer research : Gann.

[38]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[39]  R. Foà,et al.  Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. , 1996, Blood.

[40]  R. White,et al.  Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[42]  H. Afif,et al.  Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism. , 2005, Arthritis and rheumatism.

[43]  Lisa L. Smith,et al.  A Novel Celecoxib Derivative , OSU 03012 , Induces Cytotoxicity in Primary CLL Cells and Transformed B-cell Lymphoma via a Caspase and Bcl-2 Independent Mechanism , 2004 .

[44]  J. Byrd,et al.  Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. , 2002, Seminars in oncology.

[45]  C. Nzerue.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[46]  M. Hurme,et al.  Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. , 2000, Haematologica.

[47]  J. Mazuski,et al.  The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. , 1999, The Journal of surgical research.

[48]  K. Schrör,et al.  Cyclooxygenase-2 expression in human esophageal carcinoma. , 1999, Cancer research.

[49]  D. Maraninchi,et al.  Increased prostaglandin E production in malignant lymphomas. , 1985, Acta haematologica.

[50]  T. Westfall,et al.  ALTERATIONS IN THE , 1985 .